Replies to post #140437 on Biotech Values

[DewDiligence]

BMY trades 2.2% higher premarket after the company releases data today at the European Association for the Study of Liver Disease (EASL) annual meeting showing strong data on its GS-7977 Hepatitis C candidate.

Error in that news blurb insofar as GS7977 is not BMY’s drug. What the blurb meant to say is that the regimen of GS7977 plus BMY’s NS5A inhibitor, daclatasvir, produced a 100% SVR rate.